{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:34:42Z","timestamp":1773916482912,"version":"3.50.1"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["AI111805"],"award-info":[{"award-number":["AI111805"]}]},{"name":"NIH","award":["AI091514"],"award-info":[{"award-number":["AI091514"]}]},{"name":"NIH","award":["AI122942"],"award-info":[{"award-number":["AI122942"]}]},{"name":"NIH","award":["AI127089"],"award-info":[{"award-number":["AI127089"]}]},{"name":"NIH","award":["AI131365"],"award-info":[{"award-number":["AI131365"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>A novel HIV-1 vaccine candidate under development targeting the highly conserved protease cleavage regions reduced viral acquisition and delayed disease progression in a macaque SIV-challenge model. Breakthrough virus isolated from vaccinees and control animals were sequenced in the regions surrounding the SIV protease cleavages. We identified unique viral mutations that were associated with alterations in viral load and maintenance of CD4+ T cell counts in vaccinees. To evaluate whether the vaccine-elicited mutations were detrimental to virus fitness, we produced 11 mutant constructs and transfection-derived viral stocks harboring mutations in both PCS2 (in CA\/p2) and PCS12 (in Nef) that had emerged at high frequency during breakthrough viremia. Virus preparations harboring mutations displayed impaired proteolytic Gag processing, reduced viral RNA incorporation and p27-CA content. These mutants were also compromised in their ability to replicate in primary cells and cell lines. Interestingly, we observed only partial compensation of these PCS2 defects by downstream mutation at PCS12. In sum, we demonstrate that vaccine-elicited immunity directed to viral protease cleavage regions impair viral escape, and breakthrough virus cannot easily restore replicative fitness.<\/jats:p>","DOI":"10.3390\/v18030370","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:35:57Z","timestamp":1773740157000},"page":"370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Viral Escape from a Candidate HIV-1 Vaccine Targeting Protease Cleavage Sites Is Associated with a Dramatic Fitness Loss in SIVmac239-Infected Cynomolgus Macaques"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-2335","authenticated-orcid":false,"given":"So-Yon","family":"Lim","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma","family":"Luo","sequence":"additional","affiliation":[{"name":"Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Whitney","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Decamp, A.C., Rolland, M., Edlefsen, P.T., Sanders-Buell, E., Hall, B., Magaret, C.A., Fiore-Gartland, A.J., Juraska, M., Carpp, L.N., and Karuna, S.T. (2017). Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185959"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/QAI.0000000000000796","article-title":"Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907","volume":"71","author":"Deschamps","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hopkins, K.L., Laher, F., Otwombe, K., Churchyard, G., Bekker, L.-G., DeRosa, S., Nchabeleng, M., Mlisana, K., Kublin, J., and Gray, G. (2014). Predictors of HVTN 503 MRK-AD5 HIV-1 gag\/pol\/nef vaccine induced immune responses. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103446"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1473-3099(14)70020-9","article-title":"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: Unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study","volume":"14","author":"Gray","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"Gray","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Peiperl, L., Morgan, C., Moodie, Z., Li, H., Russell, N., Graham, B.S., Tomaras, G.D., De Rosa, S.C., McElrath, M.J., and Network, T.N.H.V.T. (2010). Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: A randomized clinical trial (HVTN 054). PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013579"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/QAI.0b013e31817236ab","article-title":"The HVTN protocol 903 vaccine preparedness study: Lessons learned in preparation for HIV vaccine efficacy trials","volume":"48","author":"Djomand","year":"2008","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.coviro.2016.02.010","article-title":"Approaches to preventative and therapeutic HIV vaccines","volume":"17","author":"Gray","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Pitisuttithum","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"PEdlefsen, P.T., Rolland, M., Hertz, T., Tovanabutra, S., Gartland, A.J., deCamp, A.C., Magaret, C.A., Ahmed, H., Gottardo, R., and Juraska, M. (2015). Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput. Biol., 11.","DOI":"10.1371\/journal.pcbi.1003973"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.1128\/JVI.01164-14","article-title":"Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial","volume":"88","author":"Gartland","year":"2014","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gottardo, R., Bailer, R.T., Korber, B.T., Gnanakaran, S., Phillips, J., Shen, X., Tomaras, G.D., Turk, E., Imholte, G., and Eckler, L. (2013). Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075665"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jis367","article-title":"Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials","volume":"206","author":"Montefiori","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/aid.2011.0240","article-title":"Evaluating immune correlates in HIV type 1 vaccine efficacy trials: What RV144 may provide","volume":"28","author":"Rolland","year":"2012","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/infdis\/jiq152","article-title":"Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: A case study for statistical issues in efficacy trials","volume":"203","author":"Gilbert","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1016\/j.vaccine.2013.04.057","article-title":"Immunogenicity of sequences around HIV-1 protease cleavage sites: Potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites","volume":"31","author":"Luo","year":"2013","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1016\/j.vaccine.2021.03.068","article-title":"Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites","volume":"39","author":"Daniel","year":"2021","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Li, H., Hai, Y., Lim, S.-Y., Toledo, N., Crecente-Campo, J., Schalk, D., Li, L., Omange, R.W., Dacoba, T.G., and Liu, L.R. (2018). Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202997"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1172\/JCI138728","article-title":"Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection","volume":"130","author":"Li","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12981-017-0174-7","article-title":"A novel HIV vaccine targeting the protease cleavage sites","volume":"14","author":"Li","year":"2017","journal-title":"AIDS Res. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1089\/088922200414992","article-title":"HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays","volume":"16","author":"Robinson","year":"2000","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_22","first-page":"75","article-title":"HIV diversity, recombination and disease progression: How does fitness \u201cfit\u201d into the puzzle?","volume":"9","author":"Tebit","year":"2007","journal-title":"AIDS Rev."},{"key":"ref_23","first-page":"83","article-title":"Virus fitness: Concept, quantification, and application to HIV population dynamics","volume":"299","author":"Arts","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature13594","article-title":"Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys","volume":"512","author":"Whitney","year":"2014","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1128\/AAC.37.5.1095","article-title":"Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group","volume":"37","author":"Japour","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Anastassopoulou, C.G., Marozsan, A.J., Matet, A., Snyder, A.D., Arts, E.J., Kuhmann, E.S., and Moore, J.P. (2007). Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030079"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ye, J., Coulouris, G., Zaretskaya, I., Cutcutache, I., Rozen, S., and Madden, T.L. (2012). Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC Bioinform., 13.","DOI":"10.1186\/1471-2105-13-134"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1128\/JVI.79.9.5721-5731.2005","article-title":"Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost","volume":"79","author":"Fernandez","year":"2005","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13901","DOI":"10.1128\/JVI.78.24.13901-13910.2004","article-title":"Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope","volume":"78","author":"Peyerl","year":"2004","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1128\/JVI.05841-11","article-title":"CD8+ T cell escape mutations in simian immunodeficiency virus SIVmac239 cause fitness defects in vivo, and many revert after transmission","volume":"85","author":"Mudd","year":"2011","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1128\/JVI.78.2.551-560.2004","article-title":"Important role for the CA-NC spacer region in the assembly of bovine immunodeficiency virus Gag protein","volume":"78","author":"Guo","year":"2004","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0005-2736(03)00163-9","article-title":"Role of HIV-1 Gag domains in viral assembly","volume":"1614","author":"Scarlata","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2174\/157016211798842125","article-title":"Role of the CD4 down-modulation activity of Nef in HIV-1 infectivity","volume":"9","author":"Doria","year":"2011","journal-title":"Curr. HIV Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1568008043339730","article-title":"Targeting the Nef induced increase of HIV infectivity","volume":"4","author":"Federico","year":"2004","journal-title":"Curr. Drug Targets Immune Endocr. Metabol. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0966-842X(94)90007-8","article-title":"The HIV-1 nef gene acts as a positive viral infectivity factor","volume":"2","author":"Miller","year":"1994","journal-title":"Trends Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.virol.2009.01.042","article-title":"Influence of extended mutations of the HIV-1 transframe protein p6 on Nef-dependent viral replication and infectivity in vitro","volume":"387","author":"Leiherer","year":"2009","journal-title":"Virology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/3\/370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:17:41Z","timestamp":1773897461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/3\/370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["v18030370"],"URL":"https:\/\/doi.org\/10.3390\/v18030370","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}